Compare Innodata Inc (INOD) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Innodata Inc trades at $62.06 (market cap $2.10B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 28× Innodata Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Innodata Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| INOD | TAK | |
|---|---|---|
Market Cap | $2.10B | $58.74B |
Volume | 989,493 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $121.50 | $19.05 |
52-Week Low | $34.45 | $13.23 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $1.86B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $63.42, down 4.26% today but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The company shows robust profitability with 42.7% gross margins and 37.7% ROE, while technical indicators suggest a bullish trend despite recent pullback. Recent developments include expansion into motion-capture AI labs and strategic board appointments, positioning the company for continued AI infrastructure growth.
The outlook remains positive with analyst consensus favoring buy ratings (66.7%) and projected revenue growth to $317M in 2026. Key risks include premium valuation metrics (P/E 47.4) and customer concentration concerns, but strong cash flow generation and expanding AI service offerings provide growth catalysts for investors seeking exposure to the data engineering sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
